Nutriband Inc. (NASDAQ:NTRB – Get Free Report)’s share price traded down 0.8% during trading on Friday. The company traded as low as $6.00 and last traded at $6.22. 27,919 shares changed hands during mid-day trading, a decline of 78% from the average session volume of 127,966 shares. The stock had previously closed at $6.27.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on NTRB shares. Wall Street Zen upgraded Nutriband to a “hold” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Nutriband in a research report on Monday, September 28th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce”.
Get Our Latest Analysis on NTRB
Nutriband Price Performance
The firm has a market cap of $75.64 million, a PE ratio of -11.74 and a beta of 1.92. The company has a 50-day simple moving average of $5.86 and a 200-day simple moving average of $4.28.
Nutriband (NASDAQ:NTRB – Get Free Report) last issued its quarterly earnings results on Friday, September 4th. The company reported ($0.07) earnings per share for the quarter. Nutriband had a negative return on equity of 109.07% and a negative net margin of 430.35%. The business had revenue of $0.44 million during the quarter.
Nutriband Company Profile
Nutriband Inc (NASDAQ:NTRB) develops and manufactures transdermal patches and other wearable drug-delivery products for pharmaceutical, over-the-counter, consumer, and wellness markets. The company’s capabilities include product development, formulation, manufacturing, packaging, and private-label services for customers seeking patch-based delivery systems.
Nutriband’s portfolio includes consumer and wellness patches, as well as prescription-focused transdermal technologies. Its AVERSA platform is designed to incorporate abuse-deterrent features into transdermal products, with the goal of helping reduce the risk of drug extraction, misuse, or abuse.
Featured Stories
- Five stocks we like better than Nutriband
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for Nutriband Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutriband and related companies with MarketBeat.com's FREE daily email newsletter.
